Human papillomavirus as a driver of head and neck cancers.
Sabatini ME, Chiocca S. · 2020
Read Human papillomavirus as a driver of head and neck cancers. by Sabatini ME, Chiocca S. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7000688.txt.
Introduction
Sabatini and Chiocca review human papillomavirus as a cause of head and neck cancers. Their review appeared in the British Journal of Cancer. The virus family holds more than 170 types that infect surface tissues. High-risk types are proven causes of cervical cancer.
A clear role is now emerging in cancers of the throat, above all the oropharynx. Virus-driven tumours differ from tobacco- and alcohol-driven ones in spread patterns, clinical behaviour, and molecular makeup. Head and neck cancers overall exceed 650,000 new cases a year worldwide. The authors detail infection across racial and ethnic groups, and differences between women and men. An outlook on care closes the review, covering diagnostic markers and targeted therapies in development.
Catalog record
| CREATOR | Sabatini ME, Chiocca S. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Human papillomavirus as a driver of head and neck cancers By Maria Elisa Sabatini, Susanna Chiocca Published in: British Journal of Cancer DOI: 10.1038/s41416-019-0602-7 ABSTRACT Abstract The human papillomavirus (HPV) family includes more than 170 different types of virus that infect stratified epithelium. High-risk HPV is well established as the primary cause of cervical cancer, but in recent years, a clear role for this virus in other malignancies is also emerging. Indeed, HPV plays a pathogenic role in a subset of head and neck cancers—mostly cancers of the oropharynx—with distinct epidemiological, clinical and molecular characteristics compared with head and neck cancers not caused by HPV. This review summarises our current understanding of HPV in these cancers, specifically detailing HPV infection in head and neck cancers within different racial/ethnic subpopulations, and the differences in various aspects of these diseases between women and men. Finally, we provide an outlook for this disease, in terms of clinical management, and consider the issues of ‘diagnostic biomarkers’ and targeted therapies. Subject terms: Head and neck cancer, Oncology BACKGROUND Head and neck cancer, or head and neck squamous cell carcinoma (HNSCC), comprises a group of malignancies that affect mucosal linings at different anatomic sites of the upper aerodigestive tract, including the nasopharynx, paranasal sinuses, oral cavity, oropharynx, hypopharynx and larynx (Fig. 1). HNSCC accounts for more than 650,000 new cases of cancer annually and more than 350,000 deaths. The classical major risk factors are tobacco and alcohol, and in the past few decades, human papillomavirus (HPV) has emerged as a novel risk factor for these cancers, especially for oropharyngeal squamous cell carcinoma (OPSCC), defining a new subtype of tumour that is distinct from HPV-negative ones. The incidence of HNSCC varies depending on the anatomical region and geographical location. For example, oral cavity and laryngeal cancers are the most common HNSCC globally, and the incidence and mortality rates are higher in Europe compared with the USA (United States of America).1 Men are significantly more likely to develop HNSCC than women with an incidence ratio ranging from 2:1 to 4:1.2 The average age of diagnosis is 50–70 years (reviewed in3). Globally, the incidence of HNSCC has increased by 36.5% over the past decade.1,4 A lower socioeconomic status and poor oral hygiene are the characteristics of HPV-negative HNSCC patients. HPV-negative HNSCC also features genomic complexity and very frequent alterations in the tumour suppressor TP53 and in cell-cycle regulators. These patients associate with unfavourable prognosis and are currently treated with standard care approaches, including cisplatin and radiation. On the contrary, HPV-positive oropharyngeal carcinoma (HNSCC/OPSCC) is generally highly susceptible to radiation and anticancer drugs and has a better prognosis. [Figure: Schematic representation of the head and neck region relevant for head and neck carcinomas.] A quarter of incident cases of HNSCC comprise OPSCC (reviewed in5,6), with HPV being an important implicated risk factor for its development. HPV infection is also associated with a small number of other HNSCC subsites. Data in this regard are quite discrepant, mostly because of insufficient details on anatomical tumour localisation and different HPV detection methods (discussed in the section below). A recent meta-analysis highlighted how the average incidence rates of HPV-positive patients with tumours of other head and neck regions excluding OPSCCs, such as larynx and oral cavity, are generally less than those for oropharyngeal tumours.7 The contribution of HPV to HNSCC is common within the tonsillar crypt in the oropharynx. Tonsillar crypt cells, similar to cervical squamocolumnar junction cells,8 are organised in a discontinuous single-layered epithelium that is more susceptible to carcinogenic transformation than cells within the oral cavity subsite. Indeed, although HPV infections are more common in the oral cavity than they are in tonsillar crypts, HPV-driven oral cavity squamous cell carcinoma (OCSCC) accounts for only 3.9% of cases, in contrast with the 47% of cases of OPSCC that are attributed to HPV (reviewed in9). Other viruses such as Epstein–Barr virus (EBV) and polyomaviruses also have a pathogenic role in HNSCC, sometimes by co-infecting with HPV, but in this review we will focus on our current understanding of HPV in these cancers, since they are currently on the rise and projected to keep increasing. We discuss differences in various aspects of HPV-positive HNSCC between women and men, and within different racial/ethnic subpopulations, before outlining clinical management and considering the issues of biomarkers and targeted therapies. THE TRUE IMPACT OF HPV ON HEAD AND NECK CANCER HPV infection and carcinogenesis The oncogenic role of HPV was first elucidated 40 years ago when zur Hausen10 discovered a link between the virus and the onset of cervical cancer. Later studies confirmed the direct role of several mucosal HPV types in the development of cervical cancer and other epithelial tumours.11–14 HPV infects the stratified squamous epithelia, both cutaneous and mucosal including skin of hands and feet, as well as the anogenital tract, mouth, throat and respiratory tract. Only 3–5% of HPV infection in the cervix gives rise to transforming infection, probably depending on the cell type of origin. The single-layered epithelial cells at the cervical squamocolumnar junctions between the columnar epithelium of the endocervix and the squamous epithelium of the ectocervix are the most susceptible cells for transforming infections (reviewed in15). Similarly, the single-layered tonsillar crypts constitute the epithelium with the highest susceptibility to cellular transformation in the head and neck region.9,16 These highly invaginated crypts are natural hosts for bacterial infections and foreign materials, driving the expression of programmed cell death-1 ligand-1 (PD-L1).17 Since PD-L1 is responsible for immune evasion by binding programmed death-1 (PD-1) receptors expressed by the cells of the immune system,18 PD-L1 overexpression in tonsils favours persistent HPV infection allowing tumorigenesis. Furthermore, in tonsillar crypts, the formation of a biofilm composed of bacterial microcolonies encased in a glycocalyx matrix contributes to the ability of HPV to escape the immune system.19 On the contrary, the stratified epithelium of the oral cavity, which is easily infected with HPV, is less susceptible to the carcinogenic transformation that leads to the onset of OCSCC.9 The HPV family consists of circular, double-stranded DNA viruses of 8000 base pairs encoding proteins involved in viral replication (E1 and E2/E4) and assembly (L1 and L2), as well as accessory proteins (E5, E6 and E7). High-risk HPV types, including HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59 and HPV68, can induce carcinogenic transformation of the infected mucosal epithelium (reviewed in20) by escaping cell-cycle checkpoints through E6- and E7-mediated degradation of p53 and Rb proteins, respectively (reviewed in21,22). E6/E7 expression is frequently associated with integration of the viral genome into DNA regions of genomic instability, followed by disruption of the E2 coding region and dysregulation of E6/E7 themselves. This enables HPV to establish persistent infections and continue to replicate, as the infected epithelial cells are terminally differentiated, but, although viral proteins are synthesised, no viral particles are produced by the virus. This nonproductive infection by HPV is key for the induction of tumorigenesis (reviewed in23). Low-risk HPV types induce mucosal infections that are commonly cleared by the host immune system. In the event that they evade innate immunity, low-risk HPVs can cause benign lesions, such as genital warts (HPV1, HPV6 and HPV11), and in sporadic cases, recurrent respiratory papillomatosis (HPV11)